FGF2 and neoplasm: Inhibiting FGF2-FGFR signaling in mice indeed improved tumor sensitivity to anti-VEGF therapy, suggesting that therapeutic strategies that target both growth factors could form a stronger anti-angiogenic intervention in cancer (192).